[Therapeutic options in metastatic renal carcinoma].
Within the scope of urogenital tract tumoral diseases, renal adenocarcinoma is the third most frequent neoplasia diagnosed in the adult population. The limited clinical presentations in early analysis and their anarchical behaviour are the cause for 50% to 60% of patients having already developed distant disease at the time of diagnosis. The only curative procedure so far is radical surgery, which is possible when there is a single metastatic site and sometimes even, depending on various factors which will be analyzed, several sites. In these occasions, the traditional therapeutic choices (Hormonotherapy, Chemotherapy, Radiotherapy) have proven to have limited or no efficacy in managing the disease. This fact, together with the successful results obtained in other tumoral processes, have allowed the clinical development of different modalities of Immunotherapy for the management of metastatic renal carcinoma, with results clearly hopeful. This work is a review of the results reported for each of the mentioned therapeutic choices, basically analyzing the role currently played by surgery and immunotherapy in the management of advanced renal carcinoma.
Fernández Aparicio
T
T
Servicio de Urologia, Hospital Universitario 12 de Octubre, Facultad de Medicina, Universidad Complutense, Madrid.
Miñana López
B
B
Carrero
V
V
Caballero
J
J
Vazquez
S
S
Calahorra
L
L
Leiva
O
O
D003131:Combined Modality Therapy; D005260:Female; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy*; D008297:Male; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging
D006728:Hormones
Opciones terapéuticas en el carcinoma renal metastásico.